The PD-MitoQUANT Project
Today, more than one million people live with Parkinson’s in Europe and this number is forecast to double by 2030. New, more effective treatments are urgently needed – but researchers and companies developing new drugs need to know more about how mitochondrial dysfunction is involved in disease progression and better models are needed for drug discovery and development.
PD-MitoQUANT is an Innovative Medicines Initiative (IMI) project that brings together academic experts, SMEs, pharmaceutical companies from the European Federation of Pharmaceutical Industries and Associations (EFPIA) and patient advocacy organisation Parkinson’s UK to:
Latest News
Publication news from DZNE
Our PI Prof. Donato A. DiMonte of the German Center for Neurodegenerative Diseases (DZNE) and co-authors Michael Helwig, Ayse Ulusoy, Angela Rollar, Sinead A. O’Sullivan, Shirley S. L. Lee, Helia Aboutalebi, Rita Pinto-Costa, Benjamin Jevans, and Michael Klinkenberg announce the publication of "Neuronal hyperactivity–induced oxidant stress promotes in vivo alpha-synuclein [...]
Check out our final newsletter!
It's hard to believe we reached the end of the project in July 2022. Our final newsletter is now out, with an update on our most recent publications and dissemination activities. You can also read about our last consortium meeting in Copenhagen, including the parting thoughts of our public [...]
Review article from DZNE published in The Lancet
"AIFM1 beyond cell death: An overview of this OXPHOSinducing factor in mitochondrial diseases," an open-access review article prepared by Lena Wischhof, Enzo Scifo, Dan Ehninger and our PD-MitoQUANT PI Daniele Bano was published in eBioMedicine, part of The Lancet Discovery Science on August 18th, 2022. The research team is based at [...]